Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synbio TechROCO:1295 -0.88%61 EV-to-EBIT is 15.70 as of Sep. 13, 2026, which is 1% above its 10-year median of 15.54. GuruFocus rates ROCO:1295 with a GF Score™ of 61/100 and a GF Value™ of NT$82.97 (Possible Value Trap). The stock has 12 warning signs investors should review. Among 369 Biotechnology companies, Synbio Tech ranks worse than 51.49% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Synbio Tech's Enterprise Value for the quarter that ended in Jun. 2026 was NT$2,802 Mil.
Synbio Tech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$181 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synbio Tech EV-to-EBIT Related Terms
Synbio Tech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Synbio Tech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1295 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Synbio Tech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synbio Tech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synbio Tech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Synbio Tech's EV-to-EBIT falls into.
Synbio Tech's current Enterprise Value is NT$2,838 Mil.
Synbio Tech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$181 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synbio Tech (ROCO:1295) has a EV-to-EBIT of 15.70 as of Sep. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Synbio Tech and its competitors. This is near median its historical median of 15.54. Over the past decade, Synbio Tech's EV-to-EBIT has ranged from 11.45 to 56.85. According to the industry distribution chart, Synbio Tech ranks #190 out of 369 companies in the Biotechnology industry, placing it in the top 51.5%.
Is Synbio Tech's EV-to-EBIT too high?
Synbio Tech's current EV-to-EBIT of 15.70 is near median its 10-year median of 15.54. Over the past 10 years, this metric has ranged from a low of 11.45 to a high of 56.85. The Biotechnology industry median EV-to-EBIT is 14.40. Synbio Tech's value of 15.70 is 9% above this industry median. Based on the distribution chart, Synbio Tech ranks #190 out of 369 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Synbio Tech has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Synbio Tech's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Synbio Tech ranks #190 out of 369 companies for EV-to-EBIT. This places Synbio Tech in the lower half of its industry. The industry median EV-to-EBIT is 14.40. Synbio Tech's value of 15.70 is 9% above this benchmark. Historically, Synbio Tech's own EV-to-EBIT has ranged from 11.45 to 56.85 over the past decade. While the company's 10-year median is 15.54 vs. the industry median of 14.40, Synbio Tech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.40, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synbio Tech's current EV-to-EBIT of 15.70 is 9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Synbio Tech and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synbio Tech's current EV-to-EBIT is 15.70, which is near median its own 10-year median of 15.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synbio Tech stock overvalued right now?
Based on GuruFocus' analysis, Synbio Tech (ROCO:1295) is currently considered Possible Value Trap. The stock's GF Value™ is NT$82.97, compared to a current price of NT$45.10 — trading 45.6% below its estimated fair value. The current EV-to-EBIT is 15.70, which is near median its 10-year median of 15.54 and 9% above the Biotechnology industry median of 14.40. Synbio Tech's overall GF Score™ is 61/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Synbio Tech (ROCO:1295), the current EV-to-EBIT is 15.70 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synbio Tech (ROCO:1295) Overvalued in 2026?
Based on GuruFocus' analysis, Synbio Tech stock appears to be undervalued.
The current stock price of NT$45.10 is trading 45.6% below its estimated GF Value™ of NT$82.97.
GuruFocus considers Synbio Tech to be Possible Value Trap.
Key valuation signals for ROCO:1295:
EV-to-EBIT: 15.70 (near median its 10-year median of 15.54)
GF Value™: NT$82.97 vs. price of NT$45.10 (45.6% below fair value)
Industry Position: 9% above the Biotechnology median (#190 of 369)
No single metric tells the full story. See the ROCO:1295 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synbio Tech Inc focus on functional research and manufacturing of probiotics for human health and economic animals. It has two reportable segments, Taiwan and Mainland China Segment to engage in the production and R&D technologies of the Taiwan Segment, including the production and sales of concentrated fermentation liquid, lactobacillus plantarum solid drinks, and lactobacillus plantarum granules for animal husbandry. It generates majority of revenue from Taiwan segment includes production and sale of lactobacillus plantarum powder, lactobacillus plantarum fermentation derivative products, probiotics dietary supplements, probiotics products for pets and economic animals, and probiotics products. It has presence in Taiwan, China, Southeast Asia, and Others.
61GF Score
Get the complete analysis for ROCO:1295
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1295 has been successfully added to your 
